

# Molteni Farmaceutici signs an exclusive agreement with Accord Healthcare for the distribution of the first approved buprenorphine plant in europe

Molteni Farmaceutici and Accord Healthcare announce the signing of an exclusive distribution agreement for the marketing of Sixmo® (buprenorphine plant). Sixmo® is an agonist therapy for the treatment of opioid addiction which consists of a subcutaneous implant with patented technology capable of releasing the active ingredient buprenorphine for six months. Approved in Europe, the drug will offer a viable treatment alternative to all those who need it.

This partnership agreement combines the experience and wealth of knowledge of Molteni Farmaceutici, holder of Sixmo's marketing authorization, in the opioid addiction market, with the widespread commercial presence of Accord Healthcare which includes an extensive team of marketing and medical scientific information. The agreement is strategically beneficial to both parties who share the common goal of improving the lives of opioid patients across Europe.

Giuseppe Seghi Recli, President of Molteni Farmaceutici, declared: "The primary objective of our company is to design and bring to the market treatments capable of improving the patient's quality of life. We believe Sixmo represents a real shift in the paradigm of treating patients with OUD (Opioid Use Disorders). This new agreement with Accord represents a further step in the growth strategy that Molteni has outlined in Europe for its therapeutic areas of reference, through significant partnerships aimed at improving patients' access to new therapeutic options for the treatment of addictions and in pain therapy".

Paul Tredwell, Accord Healthcare's Vice President Specialty Brands in Europe, Middle East and North Africa said, "This Sixmo® distribution agreement marks the beginning of a commitment by us to launch a range of treatment drugs. addiction, through our CNS (Central Nervous System) Franchise Specialty. Our mandate is to increase access to vital medications, and with Sixmo, we have the potential to make a difference in patients' lives by giving them an additional choice to their options of treatment. "